The number in the name of the vaccine tells how many strains (bacterial groups, also called serotypes) it protects against. The newest formulations, PCV15 (Vaxneuvance) and PCV 20 (Prevnar 20), were ...

Doncaster and Bassetlaw Teaching Hospitals (DBTH) is encouraging those aged 65 and over to get their shingles and ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar 13 capturing almost $6 billion of that last year from its use ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. Toward the end ...

MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease ...

Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...